Cart
sales@molnova.com
Prostaglandin G/H synthase 1 inhibitor
CAS No. 4943-86-6
Prostaglandin G/H synthase 1 inhibitor( —— )
Catalog No. M34214 CAS No. 4943-86-6
Prostaglandin G/H synthase 1 inhibitor (CP 74006) is a selective D5D inhibitor with an IC(50) value of 20 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 28 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | 36 | In Stock |
|
| 500MG | 60 | In Stock |
|
| 1G | 89 | In Stock |
|
Biological Information
-
Product NameProstaglandin G/H synthase 1 inhibitor
-
NoteResearch use only, not for human use.
-
Brief DescriptionProstaglandin G/H synthase 1 inhibitor (CP 74006) is a selective D5D inhibitor with an IC(50) value of 20 nM.
-
DescriptionCP-74006 (compound11h) is a selective Cyclooxygenase-1 inhibitor.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number4943-86-6
-
Formula Weight246.69
-
Molecular FormulaC13H11ClN2O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESNC1=C(C=CC=C1)C(=O)NC1=CC=C(Cl)C=C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Kakuta H, et al. Cyclooxygenase-1-selective inhibitors are attractive candidates for analgesics that do not cause gastric damage. design and in vitro/in vivo evaluation of a benzamide-type cyclooxygenase-1 selective inhibitor. J Med Chem. 2008;51(8):2400-2411.?
molnova catalog
related products
-
Retronecine
Retronecine acts as the better competitor for the competitive inhibition of antibodies to Retronecine.
-
3-Methoxytyramine hy...
3-Methoxytyramine hydrochloride is an inactive metabolite of dopamine which can activate trace amine associated receptor 1 (TAAR1).
-
Ergosterol peroxide
Ergosterol peroxide is an inhibitor of osteoclast differentiation, which has antiviral, trypanocidal, antitumor, and antiangiogenic actions, it can stimulate Foxo3a activity by inhibiting pAKT and c-Myc and activating pro-apoptotic protein Puma and Bax to induce cancer cell death.
